Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | BCHE | P06276 | 5/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30516781 | 0.80 | KDM4E (0.57) | BCHEKDM4ETDP1ALDH1A1KEAP1 | |
| SCHEMBL593890 | 0.79 | BCHE (0.54) | BCHEALDH1A1KEAP1PDPK1BACE1 | |
| SCHEMBL6496279 | 0.79 | BCHE (0.57) | BCHEKEAP1PDPK1LMNABACE1 | |
| SCHEMBL6015867 | 0.76 | TSHR (0.53) | TSHRBCHENPC1RAB9AKDM4E | |
| SCHEMBL5479823 | 0.76 | BCHE (0.49) | TSHRBCHEKDM4EKEAP1PDPK1 | |
| SCHEMBL859924 | 0.73 | BCHE (0.51) | BCHEKEAP1 | |
| SCHEMBL5486616 | 0.73 | KEAP1 (0.58) | BCHERAB9AKDM4EKEAP1PDPK1 | |
| SCHEMBL30741576 | 0.73 | BCHE (0.66) | BCHEKDM4EACHEALDH1A1KEAP1 | |
| SCHEMBL837183 | 0.72 | BCHE (0.50) | BCHEGAATDP1 | |
| SCHEMBL5480477 | 0.71 | TSHR (0.53) | TSHRBCHEKDM4EACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217724-B2 | Indole, indazole, and benzazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-15 | — | — | US | disclosed |
| US-7115412-B2 | Process for the preparation of optically active 7-substituted-3-(2-aminopropyl)indole derivatives and intermediates therefor | MERCIAN CORPORATION (JP) | 2006-10-03 | — | — | US | disclosed |
| US-20060063762-A1 | Indole indazole and benzazole derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2006-03-23 | — | — | US | disclosed |
| EP-1514869-A1 | INDOLE, INDAZOLE, AND BENZAZOLE DERIVATIVE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-03-16 | — | — | EP | disclosed |
| US-20030181732-A1 | Producing a tryptophan in the presence of a tryptophan-synthesizing enzyme originating in microorganisms, forming adrenergic receptors | MERCIAN CORPORATION (JP) | 2003-09-25 | — | — | US | disclosed |
| EP-1275730-A1 | PROCESS FOR PRODUCING OPTICALLY ACTIVE 7-SUBSTITUTED-3-(2-AMINOPROPYL)INDOLE DERIVATIVES AND INTERMEDIATES FOR PRODUCING THE SAME | MERCIAN CORPORATION (JP) | 2003-01-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063762-A1 | Indole indazole and benzazole derivative | ADRB3, ADRA2C, ADRB2 | TSHR 174/4885BCHE 1015/4885NPC1 2253/4885 |
| US-20030181732-A1 | Producing a tryptophan in the presence of a tryptophan-synthesizing enzyme originating in microorganisms, forming adrenergic receptors | TPH1, TPH2, SRR | TSHR 538/4885BCHE 267/4885NPC1 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.